Chicago-based PhysIQ’s AccelerateIQTM will be licensed to Janssen, a Johnson & Johnson unit so it can deploy it to collect data across its clinical studies through a range of its wearable biosensors, while also utilizing PhysIQ’s portfolio of FDA-cleared digital biomarkers and its medical-grade platform to transform raw data into clinical insight, according to a news release.
The collaboration is set to highlight the maturation of digital medicine and the strategic clinical implications of digital therapeutics for biopharma clinical and commercial teams, the companies say.
PhysIQ noted that a massive push for decentralized trials and a regulatory focus on quality of life markers have propelled biosensor data into a new category as a “must-have” data set to evaluate the safety and efficacy of pharmacotherapies.
“Continuous real-world sensor data and digital biomarkers are the new frontier of clinical development and pharma commercialization,” PhysIQ CCO Chris Economos said in the release. “We have built a platform that can accommodate the unknowns of a rapidly-evolving regulated digital medicine landscape – any sensor, any data type, and any algorithm.
“We could not be more pleased to work with Janssen as we transform real-world data into real-world insight to deliver solutions for patients, providers, and payers.”